| Literature DB >> 34511054 |
Sofie Stappers1, Britt Ceuleers1, Daan Van Brusselen2,3, Philippe Willems3,4, Brecht de Tavernier5, Anke Verlinden6.
Abstract
We discuss a case of a young woman, presenting a constellation of clinical and biochemical features meeting the current case definition of multisystem inflammatory syndrome in adults (MIS-A), 18 days after receiving her first dose of the Oxford/AstraZeneca vaccine. Therapy by means of intravenous immunoglobulins was initiated, leading to clinical and biochemical recovery. Although a relationship between MIS-A and the preceding vaccination cannot be confirmed, it can also not be excluded, given the temporal association and the fact that there were no indicators of a preceding SARS-CoV-2 infection.Entities:
Keywords: COVID-19; Multisystem inflammatory syndrome; SARS-CoV-2; vaccine
Mesh:
Substances:
Year: 2021 PMID: 34511054 DOI: 10.1080/17843286.2021.1977899
Source DB: PubMed Journal: Acta Clin Belg ISSN: 1784-3286 Impact factor: 1.682